Xencor Q1 2024 net loss $68.0M ($1.11/share); revenue down to $12.8M from $19.0M

Xencor Inc

2024-Q1 EPS reported -$1.11 revenue$12,805,000

Net loss widened to $68.0M from $60.8M YoY; diluted EPS -$1.11 vs -$1.02.
Revenue fell to $12.8M from $19.0M; non-cash royalty revenue vs prior milestone revenue.
Cash and marketable securities $646.7M at March 31, down from $697.4M at year-end 2023.
First patient dosed in Phase 1 for XmAb541 (CLDN6 x CD3) in solid tumors.
Appointed Bart Cornelissen as new CFO; expects cash runway into 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xencor Inc reported the first quarter ended March 31, 2024 results: revenue $12.8 million, net income $68.0 million, or $(1.11) on a fully diluted per share basis, EPS $(1.11) on a fully diluted per share basis.

Period: the first quarter ended March 31, 2024
Revenue: $12.8 million
Net income: $68.0 million, or $(1.11) on a fully diluted per share basis
EPS: $(1.11) on a fully diluted per share basis
Result: reported results

Exact text from the filing

marketable debt securities totaled $646.7 million as of March 31, 2024, compared to $697.4 million on December 31, 2023. Revenues for the first quarter ended March 31, 2024 were $12.8 million, compared to $19.0 million for the same period in 2023. Total revenues earned in the first quarter of 2024 included non-cash royalty revenue from Xencor’s Alexion and

View on SEC.gov

1443 earnings releases filed in the last 30 days. Browse all earnings releases →

Xencor Inc filing history →

Source: SEC EDGAR

accession 0001326732-24-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.